Holen Sie sich die Stockscreener-App
16.14
0.22%
-0.0795
Handel nachbörslich:
16.15
0.0095
+0.06%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt KVUE?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$16.22
Offen:
$16.2
24-Stunden-Volumen:
15.85M
Relative Volume:
0.60
Marktkapitalisierung:
$30.98B
Einnahmen:
$15.14B
Nettoeinkommen (Verlust:
$1.42B
KGV:
21.93
EPS:
0.7361
Netto-Cashflow:
$1.63B
1W Leistung:
-0.22%
1M Leistung:
-14.77%
6M Leistung:
-28.73%
1J Leistung:
-25.07%
1-Tages-Spanne:
$15.99
$16.41
1-Wochen-Bereich:
$15.99
$16.95
52-Wochen-Spanne:
$15.47
$25.17
Kenvue Inc Stock (KVUE) Company Profile
Firmenname
Kenvue Inc
Sektor
Telefon
908-874-1200
Adresse
1 KENVUE WAY, SUMMIT
Vergleichen Sie KVUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KVUE
Kenvue Inc
|
16.14 | 31.13B | 15.14B | 1.42B | 1.63B | 0.7361 |
|
PG
Procter Gamble Co
|
149.14 | 345.20B | 84.28B | 16.07B | 14.05B | 6.5067 |
|
UL
Unilever Plc Adr
|
61.00 | 147.33B | 64.99B | 6.71B | 6.53B | 2.4355 |
|
CL
Colgate Palmolive Co
|
78.41 | 62.22B | 20.00B | 3.05B | 3.37B | 3.5578 |
|
KMB
Kimberly Clark Corp
|
120.15 | 39.57B | 18.88B | 2.38B | 2.10B | 7.2549 |
Kenvue Inc Stock (KVUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-04-10 | Eingeleitet | Redburn Atlantic | Neutral |
| 2025-03-24 | Eingeleitet | Evercore ISI | In-line |
| 2025-01-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-12 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-09-24 | Eingeleitet | Jefferies | Buy |
| 2024-09-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-28 | Fortgesetzt | Citigroup | Neutral |
| 2024-04-11 | Eingeleitet | Bernstein | Underperform |
| 2024-04-03 | Eingeleitet | William Blair | Mkt Perform |
| 2024-03-01 | Fortgesetzt | Goldman | Neutral |
| 2023-11-17 | Eingeleitet | Piper Sandler | Neutral |
| 2023-09-11 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-09-07 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-09-06 | Eingeleitet | Argus | Hold |
| 2023-08-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-25 | Eingeleitet | Edward Jones | Buy |
| 2023-06-01 | Eingeleitet | HSBC Securities | Hold |
| 2023-05-30 | Eingeleitet | BofA Securities | Buy |
| 2023-05-30 | Eingeleitet | Citigroup | Neutral |
| 2023-05-30 | Eingeleitet | Deutsche Bank | Hold |
| 2023-05-30 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2023-05-30 | Eingeleitet | Goldman | Neutral |
| 2023-05-30 | Eingeleitet | JP Morgan | Overweight |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Eingeleitet | UBS | Neutral |
Alle ansehen
Kenvue Inc Aktie (KVUE) Neueste Nachrichten
Kenvue (NYSE:KVUE) Receives Hold (C-) Rating from Weiss Ratings - MarketBeat
Albert Invent Partners with Kenvue to Build the Future of Consumer Health Products With the Help of AI - The Globe and Mail
15M molecular structures: Albert Invent and Kenvue launch multi-year AI partnership to accelerate R&D - Stock Titan
J&J to spin off orthopedics business, raises full-year forecast - Reuters
Johnson & Johnson’s stock heads for a record after a profit beat and plans for another spinoff - MarketWatch
J&J Plans To Spin Off Its $9 Billion Orthopedics Arm - Finimize
Trump's Tylenol claims limit M&A options for parent company Kenvue - Reuters
Yousif Capital Management LLC Sells 18,897 Shares of Kenvue Inc. $KVUE - MarketBeat
Will Kenvue Inc. stock split again soonPortfolio Profit Report & Breakout Confirmation Alerts - newser.com
Will Kenvue Inc. stock maintain momentum in 20252025 Macro Impact & Verified Momentum Watchlists - newser.com
Traders Buy High Volume of Kenvue Call Options (NYSE:KVUE) - MarketBeat
Using RSI to spot recovery in Kenvue Inc.Market Movement Recap & AI Based Buy and Sell Signals - newser.com
Kenvue’s SWOT analysis: stock faces challenges amid tylenol controversy - Investing.com
Kenvue’s SWOT analysis: stock faces challenges amid tylenol controversy By Investing.com - Investing.com UK
Using data tools to time your Kenvue Inc. exit2025 Geopolitical Influence & Verified Momentum Stock Alerts - newser.com
Will Kenvue Inc. stock outperform tech sector in 2025Gold Moves & Short-Term Trading Alerts - newser.com
What high frequency data says about Kenvue Inc.Weekly Stock Analysis & AI Based Trade Execution Alerts - newser.com
What earnings revisions data tells us about Kenvue Inc.July 2025 Selloffs & AI Forecast for Swing Trade Picks - newser.com
Kenvue Inc. $KVUE Shares Bought by OFI Invest Asset Management - MarketBeat
Vest Financial LLC Has $48.74 Million Stake in Kenvue Inc. $KVUE - MarketBeat
Kenvue Inc. $KVUE Holdings Raised by Blair William & Co. IL - MarketBeat
US Bancorp DE Sells 36,862 Shares of Kenvue Inc. $KVUE - MarketBeat
Rep. Val T. Hoyle Sells Kenvue Inc. (NYSE:KVUE) Shares - MarketBeat
Moody’s Ratings Downgrades Kenvue Inc. (KVUE) Outlook from “Stable” to “Negative” - Yahoo
JPMorgan Chase & Co. Cuts Kenvue (NYSE:KVUE) Price Target to $21.00 - MarketBeat
Total Wealth Planning & Management Inc. Takes Position in Kenvue Inc. $KVUE - MarketBeat
Pinion Investment Advisors LLC Lowers Stock Position in Kenvue Inc. $KVUE - MarketBeat
Tylenol Turmoil: Partisan Politics Fuel Confusion Over Pregnancy Risks, Poll Shows - Benzinga
Kenvue (NYSE:KVUE) Price Target Lowered to $17.00 at Citigroup - MarketBeat
Comparing Kenvue Inc. in custom built stock radarsQuarterly Portfolio Report & Expert Curated Trade Setups - newser.com
Developing predictive dashboards with Kenvue Inc. dataWeekly Gains Summary & Technical Buy Zone Confirmations - newser.com
JPMorgan Adjusts Price Target on Kenvue to $21 From $24, Maintains Overweight Rating - MarketScreener
Is Kenvue Inc. (J4D) stock a buy for dividend portfoliosMarket Risk Analysis & Daily Profit Focused Screening - newser.com
What’s the recovery path for long term holders of Kenvue Inc.Weekly Trend Recap & Verified Short-Term Plans - newser.com
Columbus Macro LLC Increases Stock Holdings in Kenvue Inc. $KVUE - MarketBeat
Is This Beaten-Down Dividend King a Buy? - AOL.com
Is it too late to sell Kenvue Inc.Weekly Gains Summary & Technical Entry and Exit Tips - newser.com
Buy 2 Ideal Dividend Kings Of 25 'Safer' In October’s 56 - Seeking Alpha
How Kenvue Inc. (J4D) stock performs in easing cycles2025 Trade Ideas & Real-Time Stock Price Movement Reports - newser.com
How Kenvue (KVUE) Earned its Spot Among Today’s Most Promising Dividend Stocks - Yahoo Finance
Kenvue’s Brand Strength Tested After Johnson & Johnson Spinoff - Finimize
Citigroup Maintains Kenvue (KVUE) Neutral Recommendation - Nasdaq
Johnson & Johnson to Participate in the UBS Global Healthcare Conference - Investing News Network
Kenvue Stock Rebound: A Buying Opportunity? - timothysykes.com
Kenvue Inc. stock rises Thursday, outperforms market - MarketWatch
Bullish flow in Kenvue Inc with shares up 4.7% - TipRanks
Kenvue’s Resurgence: New Opportunities or Risks? - StocksToTrade
November 28th Options Now Available For Kenvue (KVUE) - Nasdaq
US Republicans and Democrats split on party lines on Trump's Tylenol-autism claimKFF poll - MarketScreener
Is Kenvue Inc. stock a buy in volatile marketsEntry Point & Daily Oversold Bounce Ideas - newser.com
Finanzdaten der Kenvue Inc-Aktie (KVUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.29%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):